ARTICLE | Clinical News
Glembatumumab vedotin: Ph II data
November 4, 2016 8:22 PM UTC
Data from 62 patients with unresectable stage III or IV metastatic melanoma that has progressed after checkpoint inhibitor therapy in cohort 1 of an open-label, U.S. Phase II trial showed that IV glem...